• Who we are
    • About us
    • Our values
    • Environmental, social & governance
    • Therapeutic areas
  • What we do
    • Consulting (Acsel Health)
    • HEOR & market access
    • Scientific communications
    • Creative communications
    • Patient engagement
  • Insights
  • News & Events
  • Join us
    • Careers
    • Reasons to join
  • Contact us
  • Menu Menu

Publication Library / Publications

Comorbidity and comedication burden in people living with HIV in the United States: updated findings from a contemporary cohort (2020-2024)

Objective

To describe comorbidity and comedication burden among people living with HHIV(PLWH) compared with matched people without HIV and evaluate 5-year trends among PLWH from 2020-2024.

Methods

This retrospective study used administrative claims data (01/01/2016-01/31/2025) from Optum’s de-identified Clinformatics Data Mart Database. The PLWH cohort included adults with ≥1 medical or pharmacy claim for an antiretroviral therapy (ART) agent in 2024 or, for those not treated with ART, an HIV diagnosis code alone (index date: earliest ART or HIV claim). People without HIV were matched 2:1 to PLWH based on age group, sex, race/ethnicity, region, and insurance type. Baseline characteristics, comorbidity burden, and comedication burden were compared between matched cohorts.

Results

26,078 PLWH and 52,156 matched people without HIV were included (mean age: 59 years). Compared with people without HIV, PLWH had greater baseline Quan-Charlson comorbidity index scores (mean [SD]: 1.24 [1.86] vs. 0.99 [1.85]; p < 0.001) and greater numbers of comorbid conditions (3.70 [3.63] vs. 3.14 [3.79]; p < 0.001) and non-ART comedications (9.2 [7.58] vs 7.1 [7.48]; p < 0.001). Multimorbidity (≥2 comorbidities: 66.4% vs. 53.6%) and polypharmacy (≥5 non-ART drugs: 68.5% vs. 52.7%) were significantly more prevalent in PLWH (both p < 0.001). The most prevalent comorbidities were hypertension (46.9% vs. 41.2%; p < 0.001), hyperlipidemia (46.0% vs. 34.4%; p < 0.001), and type 2 diabetes (21.8% vs. 22.1%, p = 0.393).

Conclusions

PLWH have greater comorbidity and comedication burdens than people without HIV. The findings suggest clinicians should consider these factors when choosing ART to minimize drug interactions and adverse events, thereby improving the long-term health of PLWH.

Authors S P Fleming, S Kamat, G Prajapati, K M Lee, V Chirikov, T LeMasters, P N Kumar
Journal Current Medical Research and Opinion
Therapeutic Area Infectious diseases and vaccines
Center of Excellence Real-world Evidence & Data Analytics
Year 2026
Read full article

Services

  • Consulting
  • HEOR & market access
  • Scientific communications
  • Creative communications
  • Patient engagement

Company

  • About Us
  • Our values
  • Environmental, social & governance
  • Our commitment to rare disease
  • Careers
  • Reasons to join
  • News & insights
  • Events
  • Locations & contact

Legal and Governance

  • Terms of use
  • Privacy notice
  • Cookie policy
  • IT security measures
  • Gender pay gap
  • Modern slavery statement
  • Disclosure UK – ABPI
  • Looking for OpenHealth Company?
  • Legal statements & documents
  • Global ethical business conduct code
  • Suppliers
footer-logo-mark
  • Twitter
  • Linkedin
  • Instagram
  • Facebook

© Copyright OPEN Health 2026. All rights reserved. OPEN Health is a registered trademark.

backtotop-arrow
Scroll to top